Back to Search Start Over

Bisphosphonate-treatment of secondary chronic osteomyelitis of the jaw - a case report.

Authors :
Heimes D
Kämmerer PW
Source :
Journal of surgical case reports [J Surg Case Rep] 2023 May 25; Vol. 2023 (5), pp. rjad270. Date of Electronic Publication: 2023 May 25 (Print Publication: 2023).
Publication Year :
2023

Abstract

Secondary chronic osteomyelitis (SCO) is caused by bacterial infection leading to progressive jawbone destruction. Antibiotics are used as first-line treatment; surgical therapy is usually extensive and may not provide a cure. Bisphosphonates have been reported to be successful in patients with primary nonbacterial osteomyelitis, and literature indicates promising results in SCO. A 38-year-old patient presented with a progressive mandible-destruction 17 years after wisdom tooth extraction. Several treatment attempts have been unsuccessful. Seeking a second opinion, the patient was then interdisciplinary treated with 90 mg of intravenous pamidronate every four weeks, three times. The patient did not experience side effects presenting a considerable improvement in mouth opening and reporting a dissolvent of signs of pain or infection. The MRI showed edema reduction and decreased contrast uptake. Therefore, bisphosphonate treatment of secondary chronic osteomyelitis of the jaw is a safe and effective option in selected cases after unsuccessful first- and second-line therapy.<br />Competing Interests: The authors declare no conflict of interest.<br /> (Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2023.)

Details

Language :
English
ISSN :
2042-8812
Volume :
2023
Issue :
5
Database :
MEDLINE
Journal :
Journal of surgical case reports
Publication Type :
Report
Accession number :
37251250
Full Text :
https://doi.org/10.1093/jscr/rjad270